Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

LPSN vs CDLX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LPSN Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

LPSN Overall Winner 6-Pillar Tally: LPSN 4 – 2 CDLX Matrix Metrics: LPSN 7 – 3 CDLX

As of Nov 20, 2026, LivePerson Inc (LPSN) is the stronger overall head-to-head candidate over Cardlytics, Inc. (CDLX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). LPSN carries a Unified Composite Score of 43.2/100 (HOLD) at $3.10 (19.3x Forward P/E, -31.6% operating margin), whereas CDLX carries 42.8/100 (HOLD) at $1.05 (36.5x Forward P/E, -19.3% operating margin).

  • Technical & Structure Timing Caution: LPSN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 68.3); meanwhile CDLX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 22.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LPSN vs CDLX
LPSN NASDAQ Head-to-Head Winner
LivePerson Inc
Services-Prepackaged Software
$3.10
+0.0% 1D
Market Cap $38.2M
TTM Revenue $229M
Forward P/E 19.3x
Beta / 30D Vol 1.77β · 85% Vol
Unified Composite Score
43.2 / 100 HOLD
Tech 10.0 Fund 39.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (14.8% over 20 days), RSI 68
RSI-14: 68.3 · SMA20: $2.83 · SMA50: $2.21
CDLX NASDAQ
Cardlytics, Inc. Common Stock
Services-Computer Programming, Data Processing, Etc.
$1.05
-5.41% 1D
Market Cap $6.8M
TTM Revenue $176M
Forward P/E 36.5x
Beta / 30D Vol 1.88β · 109% Vol
Unified Composite Score
42.8 / 100 HOLD
Tech 25.0 Fund 46.0 Flow 60.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.5%), weak momentum, RSI 23
RSI-14: 22.6 · SMA20: $1.63 · SMA50: $2.31

6-Pillar Scorecard Institutional Category Breakdown (LPSN 4 – 2 CDLX)

Columns: Metric · LPSN · CDLX
1. Valuation Multiples LPSN
Forward P/E 19.3x 36.5x
Trailing P/E 19.3x 36.5x
PEG Ratio 7.22x N/M
EV / Revenue 0.2x N/M
2. Growth & Scale LPSN
Revenue Growth (YoY) -11.9% -30.0%
Earnings Growth (YoY) +0.0% -56.7%
TTM Revenue (USD) $229M $176M
Market Cap $38.2M $6.8M
3. Profitability & Quality CDLX
Gross Margin 71.8% 49.7%
Operating Margin -31.6% -19.3%
Net Profit Margin -51.9% -20.8%
Return on Equity (ROE) -598.7% -513.2%
4. Balance Sheet & Cash Flow LPSN
Cash Generation (TTM) -$16M -$16M
Cash Flow Margin -7.1% -9.2%
Net Cash / Leverage -598.7% ROE -513.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning LPSN
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 71.2% (20th %ile) 0.8% (<1st %ile)
Put/Call OI Skew N/A 0.01x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat CDLX
OpEx & R&D Intensity N/A 69.0% of Rev ($121M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Software - Application Operator Advertising Agencies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LPSN (7) vs CDLX (3)
Institutional Metric LPSN CDLX Criterion Row Edge
Market Capitalization
Scale
$38.2M $6.8M Larger Scale LPSN
Trailing P/E Ratio
Valuation
19.3x 36.5x Lower Multiple LPSN
Forward P/E Ratio
Valuation
19.3x 36.5x Lower Multiple LPSN
Revenue Growth (YoY)
Growth
-11.9% -30.0% Higher Growth LPSN
Operating Margin (TTM)
Profitability
-31.6% -19.3% Higher Margin CDLX
Net Profit Margin
Profitability
-51.9% -20.8% Higher Margin CDLX
Return on Equity (ROE)
Capital Efficiency
-598.7% -513.2% Higher ROE CDLX
52-Week Range Position
Momentum
38% ($0–$8) 8% ($1–$6) Stronger Trend LPSN
Beta / 30D Volatility
Risk Regime
1.77β · 85% Vol 1.88β · 109% Vol Lower Realized Risk LPSN
Unified Institutional Score
Composite Signal
43.2 / 100 (HOLD) 42.8 / 100 (HOLD) Higher Composite LPSN
Trailing 12M Revenue (USD)
Operating Scale
$229M $176M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
71.8% 49.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
7.22x PEG · 0.2x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$16M (-598.7% ROE) -$16M (-513.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LPSN +57.57 pp
LPSN: +46.57% · CDLX: -11.0%
3M Horizon CDLX +459.45 pp
LPSN: +37.17% · CDLX: +496.62%
6M Horizon CDLX +354.2 pp
LPSN: -8.01% · CDLX: +346.19%
1Y Horizon CDLX +235.7 pp
LPSN: -34.87% · CDLX: +200.83%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period LPSN Revenue CDLX Revenue LPSN Op. Margin CDLX Op. Margin Margin Leader
FY2018 $250M $150M -9.5% -27.2% LPSN
FY2019 $290M $210M -29.8% -8.2% CDLX
FY2020 $370M $190M -24.4% -28.9% LPSN
FY2021 $470M $260M -19.9% -47.4% LPSN
FY2022 $510M $280M -43.1% -165.2% LPSN
FY2023 $400M $290M -27.7% -47.5% LPSN
FY2024 $310M $260M -58.6% -76.5% LPSN
FY2025 $240M $210M -32.3% -48.0% LPSN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LPSN CONSOLIDATION
15d in phase · OBV ACCUMULATION
Current IV 71.2%
IV Percentile 20th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact LPSN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CDLX BREAKDOWN
112d in phase · OBV NEUTRAL
Current IV 0.8%
IV Percentile <1st %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CDLX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LPSN Moat Profile Cyclical / Execution-Driven Positioning
Software - Application Operator
Competes within the Software - Application value chain with $38.2M market capitalization and -31.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CDLX Moat Profile Cyclical / Execution-Driven Positioning
Advertising Agencies Operator
Competes within the Advertising Agencies value chain with $6.8M market capitalization and -19.3% operating margin.
OpEx & R&D Reinvestment 69.0% of Rev ($121M)
90D Engineering Disclosures 0 Published

Investor FAQ LPSN vs CDLX Key Questions & Quantitative Answers

As of Nov 20, 2026, LivePerson Inc (LPSN) is the stronger overall head-to-head candidate over Cardlytics, Inc. (CDLX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). LPSN carries a Unified Composite Score of 43.2/100 (HOLD) at $3.10 (19.3x Forward P/E, -31.6% operating margin), whereas CDLX carries 42.8/100 (HOLD) at $1.05 (36.5x Forward P/E, -19.3% operating margin). Technical & Structure Timing Caution: LPSN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 68.3); meanwhile CDLX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 22.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

LPSN leads the Growth & Scale pillar: LPSN posts -11.9% YoY revenue growth and +0.0% YoY earnings growth on $229M TTM revenue (71.8% gross margin, -31.6% operating margin), compared with CDLX at -30.0% YoY revenue growth and -56.7% YoY earnings growth on $176M TTM revenue (49.7% gross margin, -19.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), LPSN cumulative revenue shifted -4.0% while CDLX shifted +40.0%. In operating R&D and SG&A reinvestment, LPSN deploys N/A (0 90-day corporate R&D disclosures) versus 69.0% of Rev ($121M) (0 disclosures) for CDLX.

LPSN screens cheaper on headline valuation multiples. LPSN trades at 19.3x Forward P/E, 19.3x Trailing P/E, 7.22x PEG, and 0.2x EV/Revenue (-7.1% FCF margin), whereas CDLX trades at 36.5x Forward P/E, 36.5x Trailing P/E, N/M PEG, and N/M EV/Revenue (-9.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LPSN (-598.7% ROE) versus CDLX (-513.2% ROE) capital efficiency.

In options market volatility and institutional positioning, LPSN carries 71.2% implied volatility (20th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.77β · 85% Vol realized risk). By comparison, CDLX carries 0.8% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.88β · 109% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.